Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.340
+0.010 (0.75%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Akebia Therapeutics Revenue
In the year 2023, Akebia Therapeutics had annual revenue of $194.62M, a decrease of -33.46%. Revenue in the quarter ending December 31, 2023 was $56.20M with 0.74% year-over-year growth.
Revenue (ttm)
$194.62M
Revenue Growth
-33.46%
P/S Ratio
1.44
Revenue / Employee
$1,165,407
Employees
167
Market Cap
280.56M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
Dec 31, 2019 | 335.00M | 127.26M | 61.26% |
Dec 31, 2018 | 207.74M | 26.52M | 14.63% |
Dec 31, 2017 | 181.23M | 179.69M | 11,706.32% |
Dec 31, 2016 | 1.54M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 28, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pulmonx | 68.68M |
Sanara MedTech | 64.99M |
Metagenomi | 44.76M |
TriSalus Life Sciences | 18.51M |
Lyra Therapeutics | 1.56M |
AKBA News
- 25 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - U.S. FDA approves Akebia's anemia drug - Reuters
- 4 weeks ago - Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis - PRNewsWire
- 6 weeks ago - Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - PRNewsWire
- 6 weeks ago - Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 3 months ago - Akebia Secures $55 Million Term Loan Financing - PRNewsWire
- 3 months ago - Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer - PRNewsWire
- 4 months ago - Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire